Almirall News and Activities

Almirall is a company listed under the stock ticker LBTSF (ES).

View the org chart displaying its 26 main executives

Most searched biographies at Almirall

• Carlos Gallardo Pique, Chairman of the Board and Chief Executive O...
• Eva-Lotta Allan, Independent Director
• Daniel Ripley, Non-Executive Director

Create your alert
to follow the executive moves at Almirall.

Almirall has 1,914 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Eli Lilly has acquired Centessa Pharmaceuticals (posted on June 24 2026).
• Polpharma has acquired Biofarm (posted on June 24 2026).
• AbbVie has announced the acquisition of Apogee Therapeutics  (posted on June 23 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Tracey Franklin - Chief People and Digital Technology Officer at Moderna
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Almirall

• Recognised Among Europe’s Climate Leaders by the Financial Times and Statista | Almirall
• Hidradenitis Suppurativa Awareness Week: making the invisible impact visible | Almirall
• World Environmwent Day: taking climate action today for a better tomorrow | Almirall
• AK Global Day: Skin Scouts — Observe, Detect, Act | Almirall
• Almirall continues partnership for second edition of the Hats On For AK initiative | Almirall
• Almirall and Barcelona Supercomputing Center expand their collaboration to accelerate innovation in medical dermatology | AlmirallBack ButtonSearch IconFilter Icon
• Almirall inaugurates offices in China to advance innovation in medical dermatology through partnerships | AlmirallBack ButtonSearch IconFilter Icon
• Almirall’s 2025 Results | AlmirallBack ButtonSearch IconFilter Icon
• Almirall announces the approval of Seysara in China for the treatment of moderate-to-severe acne | AlmirallBack ButtonSearch IconFilter Icon
• Almirall announces “LumiNE”, a phase III clinical study assessing the efficacy of Lebrikizumab for the treatment of nummular eczema | AlmirallBack ButtonSearch IconFilter Icon
• View more press releases Close

Social media about Almirall

• Almirall on Wikipedia, Google News & Yahoo Finance
• Almirall on LinkedIn, X (Twitter) & YouTube